Anti-SCF248 Antibodies for Targeted SCF–c-Kit Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases and fibrosis are inefficient and lack specificity in targeting the interaction between Stem Cell Factor (SCF) and its receptor c-Kit, which perpetuates chronic inflammation and fibrosis.
Innovation Solution
Development of antibodies and fragments that specifically bind to SCF, particularly the isoform SCF248, to block its interaction with c-Kit, inhibiting immune cell activation and fibrosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for inflammatory diseases are used, then they provide general anti-inflammatory effects, but they lack specificity in targeting the SCF-c-Kit interaction that perpetuates chronic inflammation and fibrosis
Solution Approach 1:
The patent introduces antibodies as intermediary molecules that specifically bind to SCF and block its interaction with c-Kit receptor. These antibodies act as mediators that interfere with the pathological SCF-c-Kit signaling axis without affecting other physiological pathways, thereby providing targeted therapy for chronic inflammatory and fibrotic diseases while maintaining treatment reliability and specificity.
2Object-affected harmful factors
If broad-spectrum anti-inflammatory treatments are applied, then they reduce overall inflammation, but they cannot specifically inhibit the SCF-c-Kit mediated chronic inflammatory process
Solution Approach 1:
The patent employs antibodies with specific binding properties that confer local quality to the treatment. The antibodies are designed to specifically recognize and bind to SCF or c-Kit at the molecular level, creating a localized inhibitory effect on the SCF-c-Kit interaction. This allows precise targeting of the harmful inflammatory pathway while leaving other physiological processes unaffected, thereby achieving both anti-inflammatory efficacy and targeting accuracy.
3Object-generated harmful factors
If non-specific anti-inflammatory agents are used, then they provide general symptom relief, but they fail to block the specific interaction between SCF and c-Kit that drives fibrosis
Solution Approach 1:
The patent utilizes antibodies as highly specific intermediary agents that precisely block the SCF-c-Kit interaction. These antibodies are engineered to bind with high affinity and specificity to either SCF or c-Kit, thereby interrupting the signaling pathway that leads to fibrosis. This intermediary approach ensures mechanism-specific inhibition of fibrotic processes while maintaining the ability to provide therapeutic benefit.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies effectively reduce inflammation and fibrosis by preventing SCF248 from interacting with c-Kit, thereby reducing immune cell accumulation and activation, providing a targeted treatment for chronic inflammatory and fibrotic diseases.
Implementation Method 1
anti-stem cell factor antibodies and methods of blocking the interaction between SCF and c-Kit
Data Source
AI summary
The disclosure relates to antibodies and antigen-binding fragments thereof that bind to Stem Cell Factor (SCF). The antibodies and antigen-binding fragments thereof specifically bind to SCF248. The disclosure further relates to methods for making the antibodies, and to methods of use of the antibodies including methods of treatment for inflammatory and/or fibrotic diseases and disorders.